Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 16, 2007. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding changes in beneficial interests in the company's ordinary shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of a specific share transaction rather than a financial performance report.
Material Changes
The only material change disclosed is the acquisition of a beneficial interest by Mr. R M Bondy. On October 12, 2007, he purchased 2 Ordinary shares under a Personal Equity Plan at a price of EUR 12.89 per share.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, risk factors, contingencies, or unusual items. It strictly adheres to Disclosure Rule 3.1.4R(1)(a) regarding the notification of the director's transaction.
Key Facts for Investor Verification
- Transaction Date: October 12, 2007
- Individual: Mr. R M Bondy
- Shares Acquired: 2 Ordinary shares
- Acquisition Price: EUR 12.89 per share
- Method: Personal Equity Plan
- Notification Date: October 16, 2007